文献速递心境障碍

醋酸乌利司他治疗经前期烦躁障碍的随机对照概念验证试验

Ulipristal Acetate for Treatment of Premenstrual Dysphoric Disorder: A Proof-of-Concept Randomized Controlled Trial.
PubMed 文献 · Am J Psychiatry · 2020-12-10

该多中心双盲随机对照试验纳入95例经前期烦躁障碍(PMDD)女性,比较醋酸乌利司他(UPA)5 mg/日与安慰剂连续治疗3个28天周期的效果。主要结局DRSP总分改善UPA组41%优于安慰剂组22%(均差-18%,95%CI=-29,-8),抑郁和愤怒/易激惹分量表亦改善,但躯体症状分量表无显著差异。UPA组缓解率50.0%高于安慰剂组21.1%。

要点

  • UPA 5 mg/日连续3周期使PMDD总体症状改善41%,优于安慰剂22%。
  • UPA对抑郁和愤怒/易激惹症状有效,但对躯体症状未见显著效果。
  • UPA组缓解率50.0%,安慰剂组21.1%,差异有统计学意义。

核心结论

  • 醋酸乌利司他(UPA)5 mg/日连续3个周期治疗经前期烦躁障碍(PMDD),在改善总体症状及心理症状方面优于安慰剂。
  • 若结果可重复,UPA可能成为PMDD的治疗选择,尤其针对心理症状。

研究设计与样本

  • 研究者发起的多中心、双盲、随机、平行组临床试验,纳入95例PMDD女性。
  • 受试者随机接受UPA 5 mg/日或安慰剂,连续治疗3个28天周期。
  • 主要结局为DRSP经前期总分从基线至治疗结束的变化,采用智能手机应用每日评分,并以线性混合模型分析。

主要发现

  • 治疗3个月后DRSP总分平均改善UPA组41%(SD=18),安慰剂组22%(SD=27),均差-18%(95%CI=-29,-8)。
  • DRSP抑郁症状分量表改善UPA组42%(SD=22),安慰剂组22%(SD=32)。
  • DRSP愤怒/易激惹分量表改善UPA组47%(SD=21),安慰剂组23%(SD=35)。
  • DRSP躯体症状分量表未见显著治疗效应。
  • 基于DRSP评分的缓解率UPA组50.0%(20例),安慰剂组21.1%(8例),差异有统计学意义。

临床怎么用

  • 对于PMDD患者,尤其是以抑郁和愤怒/易激惹等心理症状为主者,UPA 5 mg/日连续给药可能是一种潜在治疗选择。
  • 治疗决策需结合躯体症状的改善期望及UPA的安全性信息综合评估。

局限性

  • 研究为概念验证性试验,样本量有限(N=95),结果需在更大规模试验中重复验证。
  • 原文未报告对躯体症状无效的具体原因及其他潜在局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Premenstrual dysphoric disorder (PMDD) is a common mood disorder, characterized by distressing affective, behavioral, and somatic symptoms in the late luteal phase of the menstrual cycle. The authors investigated continuous treatment with a selective progesterone receptor modulator, ulipristal acetate (UPA), as a potential treatment for PMDD. METHODS: The authors conducted an investigator-initiated, multicenter, double-blind, randomized, parallel-group clinical trial in which women with PMDD (N=95) were treated with either 5 mg/day of UPA or placebo during three 28-day treatment cycles. The primary outcome was the change in premenstrual total score on the Daily Record of Severity of Problems (DRSP) from baseline to end of treatment. DRSP scores were captured by daily ratings using a smartphone application and were analyzed with linear mixed models for repeated measures. RESULTS: The mean improvement in DRSP score after 3 months was 41% (SD=18) in the UPA group, compared with 22% (SD=27) in the placebo group (mean difference -18%; 95% CI=-29, -8). Treatment effects were also noted for the DRSP depressive symptom subscale (42% [SD=22] compared with 22% [SD=32]) and the DRSP anger/irritability subscale (47% [SD=21] compared with 23% [SD=35]), but not for the DRSP physical symptom subscale. Remission based on DRSP score was attained by 20 women in the UPA group (50.0%) and eight women in the placebo group (21.1%) (a statistically significant difference). CONCLUSIONS: If these results are replicated, UPA could be a useful treatment for PMDD, particularly for the psychological symptoms associated with the disorder.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Comasco E, Kopp Kallner H, Bixo M, et al. Ulipristal Acetate for Treatment of Premenstrual Dysphoric Disorder: A Proof-of-Concept Randomized Controlled Trial. Am J Psychiatry. 2020. PMID: 33297719. doi:10.1176/appi.ajp.2020.20030286

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。